Latest Hotspot

Boehringer Ingelheim & Eli Lilly's SGLT2 inhibitor Empagliflozin obtains new indication approval in the European Union

27 July 2023
2 min read

On July 26, 2023, Boehringer Ingelheim and Eli Lilly and Company jointly announced that the European Union has approved Jardiance (empagliflozin) for the treatment of Chronic Kidney Disease (CKD). Empagliflozin is the first Sodium-Glucose Co-Transporter-2 (SGLT2) inhibitor to statistically significantly reduce the risk of hospitalization for any cause compared to a placebo in patients with CKD.

Empagliflozin is a new generation SGLT2 inhibitor co-developed by Boehringer Ingelheim and Eli Lilly. It reduces glucose reabsorption in the kidneys, lowers the renal glucose threshold, and promotes the excretion of glucose in the urine. In addition, empagliflozin can also prevent the reabsorption of salt to increase salt excretion in the body and reduce the fluid load on the body's vascular system. The changes in sugar, salt, and water metabolism induced by empagliflozin help reduce cardiovascular deaths in relevant patients. In the United States, empagliflozin has been approved by the FDA for the treatment of various indications, including type 2 diabetes, to reduce the risk of cardiovascular death in adult patients with type 2 diabetes and cardiovascular disease, and to reduce the risk of cardiovascular death and hospitalization in adult patients with reduced ejection fraction heart failure.

The new indication approval in the EU is based on the EMPA-KIDNEY, a randomised double-blind phase 3 international clinical trial. The trial results showed that compared to placebo, empagliflozin could reduce the risk of progression of kidney disease or cardiovascular death by 28% (HR: 0.72, 95% CI: 0.64-0.82, P<0.000001). Compared to the placebo group, the SGLT2 inhibitor can significantly reduce the risk of hospitalisation due to any cause in patients with chronic kidney disease. Empagliflozin can reduce the risk of hospitalisation by 14% (HR: 0.86, 95% CI: 0.78-0.95, P<0.0025).

图形用户界面, 应用程序

描述已自动生成

According to the information disclosed by Synapse (click the card below to directly access the SGLT2 target. After registration and login, you can get the detailed information about the investigational drugs, indications, research institutions, clinical trials, etc. under this target for free), as of July 27, 2023, there are a total of 78 investigational drugs for SGLT2 target, covering 33 kinds of indications, with 113 research institutions involved, 2050 related clinical trials, and as many as 7205 patents... We look forward to Empagliflozin playing a bigger role in hypoglycemia, cardiovascular disease, and kidney disease.

图形用户界面, 文本, 应用程序

描述已自动生成

PRGN-2012 - Therapeutic Vaccine for Recurrent Respiratory Papillomatosis
Drug Insights
4 min read
PRGN-2012 - Therapeutic Vaccine for Recurrent Respiratory Papillomatosis
27 July 2023
PRGN-2012 is a therapeutic vaccine that achieves therapeutic effects through immune stimulation.
Read →
An Overview of Vertex Pharmaceuticals's 97 Drug Pipelines ——Top 50 Pharmaceutical Companies R&D Progress
R&D Pipeline
3 min read
An Overview of Vertex Pharmaceuticals's 97 Drug Pipelines ——Top 50 Pharmaceutical Companies R&D Progress
27 July 2023
Vertex Pharmaceuticals, Inc. is a biopharmaceutical company that was founded in 1989 and is headquartered in Massachusetts, United States.
Read →
An Overview of Otsuka Holdings's 313 Drug Pipelines ——Top 50 Pharmaceutical Companies R&D Progress
R&D Pipeline
3 min read
An Overview of Otsuka Holdings's 313 Drug Pipelines ——Top 50 Pharmaceutical Companies R&D Progress
27 July 2023
Otsuka Holdings Co., Ltd. is a pharmaceutical organization based in Tokyo-to, Japan. It was founded in 1921 and has since become a prominent player in the biomedicine industry.
Read →
Targeting the Autophagy Pathway as a Potential Novel Therapy for FXS and ASD
Advanced Tech.
5 min read
Targeting the Autophagy Pathway as a Potential Novel Therapy for FXS and ASD
27 July 2023
A recent study has found that elevated levels of the protein MAP1B result in neuronal autophagy defects closely linked to human ASD. Treating FXS and ASD with rapamycin, a drug that inhibits autophagy, may be a promising potential therapy.
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.